NasdaqGS:COLLPharmaceuticals
How Collegium’s New $980 Million Credit Facility Could Reshape Collegium Pharmaceutical (COLL) Investors’ Risk Lens
In December 2025, Collegium Pharmaceutical, Inc. closed a US$980 million syndicated credit facility maturing in 2030, comprising a US$580 million initial term loan, US$300 million delayed draw term loan, and US$100 million revolver, and used the initial term loan to repay about US$581 million of existing debt.
The new facility, priced at term SOFR plus a leverage-based spread (initially SOFR plus 2.75%), is expected to lower annual interest costs while adding undrawn borrowing capacity for...